Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Trial status: Active, not recruiting Clinical Trials Identifier: NCT06914895 Trial Name: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Diabetes Type: Type 1 diabetes Trial Sponsor: Eli Lilly Why is this study important
Beyond genetics, obesity itself reduces GLP-1 secretion in a harmful cycle: excess weight dampens L-cell function, lowering hormone production, which allows more overeating, which perpetuates weight gain
In the non-mitochondrial-dependent pathway, copper ions regulate the intracellular redox state, activating various stress pathways such as NRF2/ARE and p53, affecting cell survival and death [103]
We're offering FREE consultations
Short-term use at typical doses has not been prominently associated with clinically significant zinc depletion
US$ 22.60
US$ 22.25
US$ 28.81
US$ 29.62
